Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life SciencesNSE:RPGLIFE -0.64%88 PB Ratio is 8.19 as of Jul. 22, 2026, which is 80% above its 10-year median of 4.56. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 88/100 and a GF Value™ of ₹2,364.27 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, RPG Life Sciences ranks worse than 91.1% on this metric.
RPG Life Sciences Ltd stock PB Ratio (=7.81) is close to 1-year high of 7.81.
The historical rank and industry rank for RPG Life Sciences's PB Ratio or its related term are showing as below:
NSE:RPGLIFE'
s PB Ratio Range Over the Past 10 Years
Min: 1.68 Med: 4.56 Max: 12.24
Current: 8.19
During the past 13 years, RPG Life Sciences's highest PB Ratio was 12.24. The lowest was 1.68. And the median was 4.56.
NSE:RPGLIFE's PB Ratio is ranked worse than 91.1% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs NSE:RPGLIFE: 8.19
During the past 12 months, RPG Life Sciences's average Book Value Per Share Growth Rate was 14.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 25.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 24.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of RPG Life Sciences was 27.50% per year. The lowest was -6.10% per year. And the median was 11.80% per year.
Back to Basics: PB Ratio
RPG Life Sciences (NSE:RPGLIFE) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
RPG Life Sciences PB Ratio Related Terms
RPG Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
RPG Life Sciences (NSE:RPGLIFE) has a PB Ratio of 8.19 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RPG Life Sciences and its competitors. This is 80% above median its historical median of 4.56. Over the past decade, RPG Life Sciences' PB Ratio has ranged from 1.68 to 12.24. According to the industry distribution chart, RPG Life Sciences ranks #839 out of 921 companies in the Drug Manufacturers industry, placing it in the top 91.1%.
Is RPG Life Sciences' PB Ratio too high?
RPG Life Sciences' current PB Ratio of 8.19 is 80% above median its 10-year median of 4.56. Over the past 10 years, this metric has ranged from a low of 1.68 to a high of 12.24. The Drug Manufacturers industry median PB Ratio is 1.88. RPG Life Sciences' value of 8.19 is 335.6% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #839 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, RPG Life Sciences has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #839 out of 921 companies for PB Ratio. This places RPG Life Sciences in the lower half of its industry. The industry median PB Ratio is 1.88. RPG Life Sciences' value of 8.19 is 335.6% above this benchmark. Historically, RPG Life Sciences' own PB Ratio has ranged from 1.68 to 12.24 over the past decade. While the company's 10-year median is 4.56 vs. the industry median of 1.88, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current PB Ratio of 8.19 is 335.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current PB Ratio is 8.19, which is 80% above median its own 10-year median of 4.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,364.27, compared to a current price of ₹2,997.90 — trading 26.8% above its estimated fair value. The current PB Ratio is 8.19, which is 80% above median its 10-year median of 4.56 and 335.6% above the Drug Manufacturers industry median of 1.88. RPG Life Sciences' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current PB Ratio is 8.19 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,997.90 is trading 26.8% above its estimated GF Value™ of ₹2,364.27.
GuruFocus considers RPG Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:RPGLIFE:
PB Ratio: 8.19 (80% above median its 10-year median of 4.56)
GF Value™: ₹2,364.27 vs. price of ₹2,997.90 (26.8% above fair value)
Industry Position: 335.6% above the Drug Manufacturers median (#839 of 921)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
88GF Score
Get the complete analysis for NSE:RPGLIFE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
